Matches in Wikidata for { <http://www.wikidata.org/entity/Q99405184> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- Q99405184 description "artículu científicu espublizáu n'agostu de 2020" @default.
- Q99405184 description "scientific article published on 18 August 2020" @default.
- Q99405184 description "wetenschappelijk artikel" @default.
- Q99405184 description "наукова стаття, опублікована 18 серпня 2020" @default.
- Q99405184 name "Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab" @default.
- Q99405184 name "Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab" @default.
- Q99405184 type Item @default.
- Q99405184 label "Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab" @default.
- Q99405184 label "Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab" @default.
- Q99405184 prefLabel "Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab" @default.
- Q99405184 prefLabel "Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab" @default.
- Q99405184 P1433 Q99405184-0CFEABA9-BC21-4D8C-8DA8-B4C08900C1FA @default.
- Q99405184 P1476 Q99405184-7956DA8C-DE9D-4A4D-BF4A-D481C75FCD1B @default.
- Q99405184 P2093 Q99405184-10563F06-C3FB-4563-A073-42DD5C91C8EE @default.
- Q99405184 P2093 Q99405184-1BC5979D-EB85-4735-B455-F1D38864786F @default.
- Q99405184 P2093 Q99405184-20A12226-7620-4D4E-B8F9-15A73EFB653C @default.
- Q99405184 P2093 Q99405184-33E1C49F-F808-40EE-86BE-E54D7C28009F @default.
- Q99405184 P2093 Q99405184-4FE0567E-BBE2-407F-A15F-2FEEB29EC9AC @default.
- Q99405184 P2093 Q99405184-53F097D5-4273-4958-AEFB-122F4769EC62 @default.
- Q99405184 P2093 Q99405184-5D47A2B2-0E24-4E27-B785-04B7256CFD02 @default.
- Q99405184 P2093 Q99405184-9988184A-FE24-48F4-88D6-9D69F37CA6D9 @default.
- Q99405184 P2093 Q99405184-D71CBF91-0911-47A4-BEC4-6148CF7B076A @default.
- Q99405184 P2093 Q99405184-F374301F-6D7D-4FA7-BE3A-D3B9AFFBFDF9 @default.
- Q99405184 P275 Q99405184-FD483EDA-1C6B-4886-A418-63B557EFA5F1 @default.
- Q99405184 P304 Q99405184-8FE8227B-786B-4C68-A277-DB78D38FD8A8 @default.
- Q99405184 P31 Q99405184-A64A3556-EDD4-4C06-A5DF-F4A8A7B1B251 @default.
- Q99405184 P356 Q99405184-4B21D229-691E-46AB-99CB-A530738D1421 @default.
- Q99405184 P478 Q99405184-A758280F-7D8E-4CE5-8612-EB48B88099C2 @default.
- Q99405184 P50 Q99405184-0242A0C5-47C5-4E31-A1D8-61BD1C8406F5 @default.
- Q99405184 P50 Q99405184-3DFE549E-94D7-4553-8F5D-61CF3D642EB0 @default.
- Q99405184 P577 Q99405184-909940CE-080F-4084-855F-DDAF51391E80 @default.
- Q99405184 P6216 Q99405184-D921E014-6C48-43D6-B213-32B71224B342 @default.
- Q99405184 P698 Q99405184-98738951-8CF6-4BA3-A81A-73DB50A00E81 @default.
- Q99405184 P921 Q99405184-204C5EF3-DC1E-49C1-9062-08475D36798A @default.
- Q99405184 P921 Q99405184-55BCE509-9526-4506-A93D-1BCA7CE8DC30 @default.
- Q99405184 P921 Q99405184-E9836BCC-5B13-43FA-8755-A243458E2F32 @default.
- Q99405184 P921 Q99405184-FE0A2B7A-6C57-46D7-ACCC-7B05640C0BF9 @default.
- Q99405184 P356 1758835920928635 @default.
- Q99405184 P698 32922518 @default.
- Q99405184 P1433 Q26842113 @default.
- Q99405184 P1476 "Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC" @default.
- Q99405184 P2093 "Armin Gerger" @default.
- Q99405184 P2093 "Florian Posch" @default.
- Q99405184 P2093 "Gerald Prager" @default.
- Q99405184 P2093 "Jakob Riedl" @default.
- Q99405184 P2093 "Leonhard Müllauer" @default.
- Q99405184 P2093 "Margit Schmeidl" @default.
- Q99405184 P2093 "Matthias Unseld" @default.
- Q99405184 P2093 "Merima Herac" @default.
- Q99405184 P2093 "Robert Brettner" @default.
- Q99405184 P2093 "Werner Scheithauer" @default.
- Q99405184 P275 Q34179348 @default.
- Q99405184 P304 "1758835920928635" @default.
- Q99405184 P31 Q13442814 @default.
- Q99405184 P356 "10.1177/1758835920928635" @default.
- Q99405184 P478 "12" @default.
- Q99405184 P50 Q59817050 @default.
- Q99405184 P50 Q93062199 @default.
- Q99405184 P577 "2020-08-18T00:00:00Z" @default.
- Q99405184 P6216 Q50423863 @default.
- Q99405184 P698 "32922518" @default.
- Q99405184 P921 Q108566365 @default.
- Q99405184 P921 Q412197 @default.
- Q99405184 P921 Q413299 @default.
- Q99405184 P921 Q420207 @default.